B Cell Lymphoma

Conference Coverage

CLL: The initial work-up

CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.


Combo appears safe, active in rel/ref NHL

The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or...